Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01062230
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class
Stopped
Slow accrual; PI left primary institution
Conditions
Multiple Myeloma
Interventions
DRUG:
Bortezomib (Velcade)
Sponsor
University of Arkansas
Collaborators
[object Object]